Fibroblast growth factor receptor (FGFR) gene amplifications are rare events in bladder cancer

Histopathology

Volumn 66, Issue 5, 2015, Pages 639-649

  Fischbach, Anna ^a   Rogler, Anja ^b   Erber, Ramona ^b   Stoehr, Robert ^b   Poulsom, Richard ^c   Heidenreich, Axel ^a   Schneevoigt, Birte Swantje ^d   Hauke, Sven ^e   Hartmann, Arndt ^b   Knuechel, Ruth ^a   Veeck, Jürgen ^a   Gaisa, Nadine T ^a  

^a RWTH AACHEN UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^d LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^e ZytoVision GmbH   (Germany)

Author keywords

Amplification; Bladder cancer; FGFR1; FGFR2; FGFR3

Indexed keywords

FIBROBLAST GROWTH FACTOR RECEPTOR 1; FIBROBLAST GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 3; FGFR1 PROTEIN, HUMAN; FGFR2 PROTEIN, HUMAN; FGFR3 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER GRADING; CANCER STAGING; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; VERY ELDERLY; ADOLESCENT; BLADDER TUMOR; CHILD; GENETICS; INFANT; MUTATION; NEWBORN; PRESCHOOL CHILD; PROCEDURES; TISSUE MICROARRAY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; FEMALE; GENE AMPLIFICATION; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; MUTATION; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 1; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 2; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 3; TISSUE ARRAY ANALYSIS; URINARY BLADDER NEOPLASMS; YOUNG ADULT;

EID: 84924633293     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/his.12473     Document Type: Article

References (42)

1. Kaatsch P, Spix C, Hentschel S et al. Harnblase. In Krebs in Deutschland 2009/2010, 9th edn. Berlin: Robert Koch-Institut und die Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V., 2013; 100-102.
2. di Martino E, Tomlinson DC, Knowles MA. A Decade of FGF receptor research in bladder cancer: past, present, and future challenges. Adv. Urol. 2012; 2012; 429213 doi:1155/2012/429213.
3. Cappellen D, De Oliveira C, Ricol D et al. Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat. Genet. 1999; 23; 18-20.
4. vanOers JMM, Adam C, Denzinger S et al. Chromosome 9 deletions are more frequent than FGFR3 mutations in flat urothelial hyperplasias of the bladder. Int. J. Cancer 2006; 119; 1212-1215.
5. van Rhijn BWG, Montironi R, Zwarthoff EC, Jöbsis AC, van der Kwast TH. Frequent FGFR3 mutations in urothelial papilloma. J. Pathol. 2002; 198; 245-251.
6. Hernandez S, Lopez-Knowles E, Lloreta J et al. Prospective study of FGFR3 mutations as a prognostic factor in nonmuscle invasive urothelial bladder carcinomas. J. Clin. Oncol. 2006; 24; 3664-3671.
7. Billerey C, Chopin D, Aubriot-Lorton MH et al. Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors. Am. J. Pathol. 2001; 158; 1955-1959.
8. Burger M, van der Aa MN, van Oers JM et al. Prediction of progression of non-muscle-invasive bladder cancer by WHO 1973 and 2004 grading and by FGFR3 mutation status: a prospective study. Eur. Urol. 2008; 54; 835-843.
9. van Rhijn BW, van der Kwast TH, Liu L et al. The FGFR3 mutation is related to favorable pT1 bladder cancer. J. Urol. 2012; 187; 310-314.
10. Tomlinson DC, Baldo O, Harnden P, Knowles MA. FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer. J. Pathol. 2007; 213; 91-98.
11. Bodoor K, Ghabkari A, Jaradat Z et al. FGFR3 mutational status and protein expression in patients with bladder cancer in a Jordanian population. Cancer Epidemiol. 2010; 34; 724-732.
12. Tomlinson DC, Lamont FR, Shnyder SD, Knowles MA. Fibroblast growth factor receptor 1 promotes proliferation and survival via activation of the mitogen activated protein kinase pathway in bladder cancer. Cancer Res. 2009; 69; 4613-4620.
13. Simon R, Richter J, Wagner U et al. High-throughput tissue microarray analysis of 3p25 (RAF1) and 8p12 (FGFR1) copy number alterations in urinary bladder cancer. Cancer Res. 2001; 61; 4514-4519.
14. de Medina SGD, Chopin D, El Marjou A et al. Decreased expression of keratinocyte growth factor receptor in a subset of human transitional cell bladder carcinomas. Oncogene 1997; 14; 323-330.
15. Qing J, Du X, Chen Y et al. Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice. J. Clin. Invest. 2009; 119; 1216-1229.
16. Lamont FR, Tomlinson DC, Cooper PA, Shnyder SD, Chester JD, Knowles MA. Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo. Br. J. Cancer 2011; 104; 75-82.
17. Liang G, Chen G, Wei X, Zhao Y, Li X. Small molecule inhibition of fibroblast growth factor receptors in cancer. Cytokine Growth Factor Rev. 2013; 24; 467-475.
18. Guagnano V, Furet P, Spanka C et al. Discovery of 3-(2, 6-dichloro-3, 5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamin o]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase. J. Med. Chem. 2011; 54; 7066-7083.
19. Heroult M, Ellinghaus P, Sieg C et al. Preclinical profile of BAY 1163877 - a selective pan-FGFR inhibitor in phase 1 clinical trial [Abstract]. In Proceedings of the 105th Annual Meeting of the American Association for Cancer Research, 5-9 April 2014. San Diego, CA. Philadelphia (PA): AACR; 2014. Abstract no. 1739.
20. Wittekind C, Meyer H-J eds. UICC TNM: Klassifikation maligner Tumoren, 7th edn. Weinheim: Wiley-Blackwell, 2010; 246-249.
21. Eble JN, Sauter G, Epstein JI, Sesterhenn IA eds. World Health Organization classification of tumours. Pathology and genetics of tumours of the urinary system and male genital organs. Lyon: IARC Press, 2004; 89-157.
22. Schildhaus HU, Heukamp LC, Merkelbach-Bruse S et al. Definition of a fluorescence in-situ hybridization score identifies high- and low-level FGFR1 amplification types in squamous cell lung cancer. Mod. Pathol. 2012; 25; 1473-1480.
23. van Oers JM, Lurkin I, van Exsel AJ et al. A simple and fast method for the simultaneous detection of nine fibroblast growth factor receptor 3 mutations in bladder cancer and voided urine. Clin. Cancer Res. 2005; 11; 7743-7748.
24. Hafner C, van Oers JM, Vogt T et al. Mosaicism of activating FGFR3 mutations in human skin causes epidermal nevi. J. Clin. Invest. 2006; 116; 2201-2207.
25. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 2014; 507; 315-322.
26. Marchiò C, Lambros MB, Gugliotta P et al. Does chromosome 17 centromere copy number predict polysomy in breast cancer? A fluorescence in situ hybridization and microarray-based CGH analysis. J. Pathol. 2009; 219; 16-24.
27. Elbauomy Elsheikh S, Green AR, Lambros MB et al. FGFR1 amplification in breast carcinomas: a chromogenic in situ hybridisation analysis. Breast Cancer Res. 2007; 9; R23.
28. Catto JW, Miah S, Owen HC et al. Distinct microRNA alterations characterize high- and low-grade bladder cancer. Cancer Res. 2009; 69; 8472-8481.
29. Larsson C, Grundberg I, Söderberg O et al. In situ detection and genotyping of individual mRNA molecules. Nat. Methods 2010; 7; 395-397.
30. Nord H, Segersten U, Sandgren J et al. Focal amplifications are associated with high grade and recurrences in stage Ta bladder carcinoma. Int. J. Cancer 2010; 126; 1390-1402.
31. Chekaluk Y, Wu CL, Rosenberg J et al. Identification of nine genomic regions of amplification in urothelial carcinoma, correlation with stage, and potential prognostic and therapeutic value. PLoS ONE 2013; 8; e60927.
32. Shen H, Morrison CD, Zhang J et al. 6p22.3 amplification as a biomarker and potential therapeutic target of advanced stage bladder cancer. Oncotarget 2013; 4; 2124-2134.
33. López V, González-Peramato P, Suela J et al. Identification of prefoldin amplification (1q23.3-q24.1) in bladder cancer using comparative genomic hybridization (CGH) arrays of urinary DNA. J. Transl. Med. 2013; 11; 182.
34. Beltran AL, Ordonez JL, Otero AP et al. Fluorescence in situ hybridization analysis of CCND3 gene as marker of progression in bladder carcinoma. J. Biol. Regul. Homeost. Agents 2013; 27; 559-567.
35. Chen PC, Yu HJ, Chang YH, Pan CC. Her2 amplification distinguishes a subset of non-muscle-invasive bladder cancers with a high risk of progression. J. Clin. Pathol. 2013; 66; 113-119.
36. Laé M, Couturier J, Oudard S et al. Assessing HER2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: results in 1005 patients. Ann. Oncol. 2010; 21; 815-819.
37. Fleischmann A, Rotzer D, Seiler R, Studer UE, Thalmann GN. Her2 amplification is significantly more frequent in lymph node metastases from urothelial bladder cancer than in the primary tumours. Eur. Urol. 2011; 60; 350-357.
38. Perera T, Jovcheva E, Vialard J et al. JNJ-42756493 is an inhibitor of FGFR-1, 2, 3 and 4 with nanomolar affinity for targeted therapy [Abstract]. In Proceedings of the 105th Annual Meeting of the American Association for Cancer Research, 5-9 April 2014. San Diego, CA. Philadelphia (PA): AACR; 2014. Abstract no. 1738.
39. Tie J, Bang Y-J, Park YS et al. A phase I trial of LY2874455, a fibroblast growth factor receptor inhibitor, in patients with advanced cancer [Abstract]. In Proceedings of the 105th Annual Meeting of the American Association for Cancer Research, 5-9 April 2014. San Diego, CA. Philadelphia (PA): AACR; 2014. Abstract no. CT215.
40. Parker BC, Annala MJ, Cogdell DE et al. The tumorigenic FGFR3-TACC3 gene fusion escapes miR-99a regulation in glioblastoma. J. Clin. Invest. 2013; 123; 855-865.
41. Wu YM, Su F, Kalyana-Sundaram S et al. Identification of targetable FGFR gene fusions in diverse cancers. Cancer Discov. 2013; 3; 636-647.
42. Williams SV, Hurst CD, Knowles MA. Oncogenic FGFR3 gene fusions in bladder cancer. Hum. Mol. Genet. 2013; 22; 795-803.